2018
Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need?
Pagnesi M, Regazzoli D, Ancona MB, Mangieri A, Lanzillo G, Giannini F, Buzzatti N, Prendergast BD, Kodali S, Lansky AJ, Colombo A, Latib A. Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need? JACC Cardiovascular Interventions 2018, 11: 517-528. PMID: 29566796, DOI: 10.1016/j.jcin.2017.12.018.Peer-Reviewed Original ResearchConceptsTranscatheter mitral valve interventionsCerebral embolic riskMitral valve interventionMV proceduresEmbolic riskValve interventionHeart interventionsProcedure-related adverse eventsPatient-related factorsStructural heart interventionsReal clinical issueMV interventionAdverse eventsEmbolic injuryMV diseaseUnmet ClinicalMV anatomyClinical issuesAvailable evidenceInterventionRiskSystematic assessmentClinicalInjuryAvailable data
2014
Almanac 2013: novel non-coronary cardiac interventions.
Meier P, Franzen O, Lansky AJ. Almanac 2013: novel non-coronary cardiac interventions. Turk Kardiyoloji Dernegi Arsivi-Archives Of The Turkish Society Of Cardiology 2014, 42: 203-15. PMID: 24643156, DOI: 10.5543/tkda.2014..Peer-Reviewed Original ResearchMeSH KeywordsAortic Valve StenosisAtrial AppendageCardiac Surgical ProceduresHumansMitral Valve InsufficiencyConceptsHigh riskPercutaneous left atrial appendage closureImportant new treatment optionInterventional cardiologyLeft atrial appendage closureNon-pharmacologic therapiesAtrial appendage closureAortic valve stenosisCoronary artery diseaseAortic valve diseaseSurgical valve repairNew treatment optionsImportant clinical evidenceRecent clinical dataRenal denervationResistant hypertensionStroke preventionAppendage closureElderly patientsArtery diseasePercutaneous treatmentValve stenosisValvular diseaseValve diseaseClinical evidence
2013
Almanac 2013: novel non-coronary cardiac interventions
Meier P, Franzen O, Lansky AJ. Almanac 2013: novel non-coronary cardiac interventions. The Anatolian Journal Of Cardiology 2013, 13: 622-31. PMID: 24064106, DOI: 10.5152/akd.2013.224.Peer-Reviewed Original ResearchMeSH KeywordsAortic Valve StenosisAtrial AppendageAtrial FibrillationHumansHypertension, RenalMitral Valve InsufficiencyPercutaneous Coronary InterventionConceptsHigh riskPercutaneous left atrial appendage closureImportant new treatment optionInterventional cardiologyLeft atrial appendage closureNon-pharmacologic therapiesAtrial appendage closureAortic valve stenosisCoronary artery diseaseAortic valve diseaseSurgical valve repairNew treatment optionsImportant clinical evidenceRecent clinical dataRenal denervationResistant hypertensionStroke preventionAppendage closureElderly patientsArtery diseasePercutaneous treatmentValve stenosisValvular diseaseValve diseaseClinical evidenceAlmanac 2013: Novel non-coronary cardiac interventions
Meier P, Franzen O, Lansky AJ. Almanac 2013: Novel non-coronary cardiac interventions. Heart 2013, 99: 1309. PMID: 23899781, DOI: 10.1136/heartjnl-2013-304430.Peer-Reviewed Original ResearchMeSH KeywordsAortic Valve StenosisAtrial AppendageAtrial FibrillationCardiologyDenervationEmbolic Protection DevicesEquipment DesignHeart DiseasesHeart Valve DiseasesHeart Valve Prosthesis ImplantationHumansKidneyMitral Valve InsufficiencyPercutaneous Coronary InterventionSeptal Occluder DeviceTreatment OutcomeConceptsHigh riskPercutaneous left atrial appendage closureImportant new treatment optionInterventional cardiologyLeft atrial appendage closureNon-pharmacologic therapiesAtrial appendage closureAortic valve stenosisCoronary artery diseaseAortic valve diseaseSurgical valve repairNew treatment optionsImportant clinical evidenceRecent clinical dataRenal denervationResistant hypertensionStroke preventionAppendage closureElderly patientsArtery diseasePercutaneous treatmentValve stenosisValvular diseaseValve diseaseClinical evidence
2004
Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Journal Of The American College Of Cardiology 2004, 43: 1368-1374. PMID: 15093869, DOI: 10.1016/j.jacc.2003.11.046.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionPlatelet Aggregation InhibitorsPrognosisProspective StudiesSeverity of Illness IndexStentsSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionLeft ventricular ejection fractionMechanical reperfusion therapySevere mitral regurgitationMitral regurgitationIndex procedureReperfusion therapyIndependent predictorsMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialPresence of MRHigher Killip classMechanical reperfusion strategiesNon-shock patientsHigh-risk patientsLong-term mortalityTriple vessel diseasePercutaneous coronary interventionVentricular ejection fractionMild mitral regurgitationControlled AbciximabKillip classReperfusion strategyComplications TrialCoronary intervention